People in the News
Roche announced that Paul Bulcke, a member of the company's board of directors since 2011, has decided not to stand for reelection at its general meeting in 2022. The company proposed Jemilah Mahmood as a replacement. Mahmood is currently the special advisor on public health to Malaysia's prime minister and serves as pro-chancellor of Heriot-Watt University of Malaysia. She is also a professor at and executive director of Sunway Centre for Planetary Health.
Bulcke is the chairman and former CEO of Nestlé and has worked at the firm since 1979. He is also a member of the European Roundtable for Industry and the JP Morgan International Council.
Oliver Dick has been appointed as chief operating officer of Resolve Biosciences. He comes to the spatial biology firm from Miltenyi Biotec, where he held the same position. Prior to that, he spent more than 12 years at Qiagen, where he was VP of global manufacturing for life sciences and diagnostics. Before joining Qiagen, he held management positions at Rentschler Biotechnologies, Pharmaplan, and the Pall Corporation. Dick holds a PhD in chemical and bioprocess engineering from Technical University of Dortmund in Germany.
Becton Dickinson has named Joseph Smith as senior VP and CSO. Smith previously served as president and CEO of holding company Digital Health, where he was responsible for the firm's strategy to invest in or acquire digital health and therapeutic technologies. Smith has also held medical, scientific, and technology leadership positions at Johnson & Johnson, Boston Scientific, and the West Health Institute, and has served as academic faculty at Washington University School of Medicine and the school's Department of Biomedical Engineering.
Scott O'Brien has been appointed as chief commercial officer of Specific Diagnostics. Most recently, he was senior VP of global marketing and international sales at GenMark Diagnostics, which was acquired by Roche Diagnostics earlier this year. Prior to joining GenMark 10 years ago, he held various roles at Illumina, Agilent Technologies, and Stratagene. O'Brien holds a BS in microbiology from the University of Wisconsin-Madison.
SomaLogic has hired Steve Mermelstein as SVP of corporate strategy, development and mergers and acquisitions. He was previously VP of strategy and corporate development at Agilent Technologies. Before that, Mermelstein was managing director at Covington Associates, and he was managing director at Huron Consulting Group.
Meridian Bioscience announced that Executive VP, Secretary, and CFO Bryan Baldasare will retire, effective Dec. 31. The company is currently looking for a new CFO, and Julie Smith has been appointed SVP controller, effective Dec. 6, and principal accounting officer, effective Jan. 1.
Baldasare joined Meridian in 2000 and has served as CFO since 2019. Before becoming CFO, he was the company's chief accounting officer and corporate controller and treasurer. Prior to working at Meridian, he was a senior audit manager at accounting firm Arthur Andersen.
Albert Li will join Discovery Life Sciences as CSO of pharmacology and toxicology as part of the firm's recent acquisition of In Vitro ADMET Laboratories (IVAL). Li, who founded IVAL in 2004, has been pioneering the isolation, cryopreservation, and culturing of human hepatocytes and their use in evaluating drug metabolism, drug-drug interactions, and drug toxicity.
Meeta Gulyani has been appointed to the board of directors of Seer. She is the executive VP and head of strategy, business development, and transformation for the life science business of Merck KGaA in Germany, which operates as MilliporeSigma in the US and Canada. Previously, she was executive VP and head of strategy and global franchises for the biopharma business of Merck KGaA, and before that, general manager for Roche South Asia as well as VP and head of global portfolio management at Roche. Gulyani holds an MBA from the Asian Institute of Management in the Philippines and a bachelor's degree in economics from the Shri Ram College of Commerce at Delhi University in India.
OncoHost said that David Gandara has joined its scientific advisory board. Gandara currently serves as director of the thoracic oncology program at the University of California Davis Comprehensive Cancer Center, as well as a professor of medicine, and senior adviser to the cancer center's director.
Gandara brings deep knowledge to the field of personalized cancer care, focused on investigating new anticancer agents and biomarkers in a variety of novel drug classes, OncoHost said. He is a co-leader of Lung MAP, a precision medicine umbrella clinical trial for the development of biomarker-driven strategies for new therapies in lung cancer. Gandara was also recently appointed chief medical officer of the International Society for Liquid Biopsy, and previously served as president of the International Association for Study of Lung Cancer, and as treasurer and board member for the American Society of Clinical Oncology.
Padma Kodukula has joined A-Alpha Bio as chief business officer. She will be responsible for executing the company's overall corporate and business strategy, in particular the development and expansion of strategic partnerships with pharma and biotech firms. She comes to A-Alpha Bio from Precision NanoSystems, which was acquired by Danaher in June, where she closed various business partnerships. Prior to that, she held business development roles at Human Longevity, Life Technologies, and Prometheus Laboratories. Kodukula holds a PhD in immunology from the University of Chicago and an MBA from San Diego State University.